Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prostate cancer treatment best based on life-expectancy

This article was originally published in Clinica

Executive Summary

Prostate cancer patients with "long life-expectancies who are not a great surgical risk and who have a preference to undergo surgery" are most likely to benefit from radical prostatectomy. Those with "long life expectancy, no risk factors for the treatment, and a preference for radiation therapy" will most likely benefit from this type of treatment, while patients with shorter life-expectancy and/or low grade tumours may benefit most from surveillance. These are the conclusions of the Prostate Cancer Clinical Guidelines Panel of the American Urological Association (Journal of Urology, Vol. 154, pp. 2144-2148).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT094525

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel